NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients
Phase 3
Active, not recruiting
- Conditions
- Anal Basaloid CarcinomaAnal Canal Cloacogenic CarcinomaMetastatic Anal Squamous Cell CarcinomaRecurrent Anal Squamous Cell CarcinomaStage III Anal Cancer AJCC v8Stage IV Anal Cancer AJCC v8Unresectable Anal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 205
- Registration Number
- NCT04444921
- Locations
- 🇺🇸
Walter Knox Memorial Hospital, Emmett, Idaho, United States
🇺🇸Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Cancer/Tumor Pain
Completed
- Conditions
- Solid TumorsNeoplasmsCancer
- First Posted Date
- 2020-06-22
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 83
- Registration Number
- NCT04442425
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
Phase 2
Active, not recruiting
- Conditions
- Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRefractory LymphomaRefractory Malignant Solid Neoplasm
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT04439201
- Locations
- 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
Phase 2
Active, not recruiting
- Conditions
- Advanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmAdvanced LymphomaRefractory LymphomaRefractory Malignant Solid NeoplasmRefractory Multiple Myeloma
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT04439175
- Locations
- 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)
Phase 2
Completed
- Conditions
- Refractory LymphomaRefractory Malignant Solid NeoplasmRefractory Plasma Cell MyelomaAdvanced LymphomaHematopoietic and Lymphoid Cell NeoplasmAdvanced Malignant Solid Neoplasm
- Interventions
- Biological: Nivolumab
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2021-04-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 47
- Registration Number
- NCT04439214
- Locations
- 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)
Phase 2
Active, not recruiting
- Conditions
- Advanced Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmRefractory Multiple MyelomaAdvanced LymphomaHematopoietic and Lymphoid Cell NeoplasmRefractory Lymphoma
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT04439279
- Locations
- 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)
Phase 2
Active, not recruiting
- Conditions
- Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRefractory LymphomaRefractory Malignant Solid NeoplasmRefractory Multiple Myeloma
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT04439136
- Locations
- 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
Phase 2
Active, not recruiting
- Conditions
- Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRefractory LymphomaRefractory Malignant Solid NeoplasmRefractory Multiple Myeloma
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 5
- Registration Number
- NCT04439266
- Locations
- 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)
Phase 2
Active, not recruiting
- Conditions
- Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRefractory LymphomaRefractory Malignant Solid NeoplasmRefractory Multiple Myeloma
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 4
- Registration Number
- NCT04439357
- Locations
- 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)
Phase 2
Active, not recruiting
- Conditions
- Advanced LymphomaHematopoietic and Lymphoid Cell NeoplasmRefractory LymphomaRefractory Malignant Solid NeoplasmRefractory Multiple MyelomaAdvanced Malignant Solid Neoplasm
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT04439227
- Locations
- 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath